Matthew V N OSullivan
Overview
Explore the profile of Matthew V N OSullivan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalo E, Basyouni Z, Katz G, Karkvandi V, Watson L, Crowther H, et al.
J Med Virol
. 2025 Feb;
97(2):e70235.
PMID: 39945377
Laboratory-based findings suggest that Sotrovimab is significantly less effective against emerging CARS-CoV-2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED)...
2.
The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: A cross-sectional study
Koirala A, McRae J, Britton P, Downes M, Prasad S, Nicholson S, et al.
PLoS One
. 2024 Sep;
19(9):e0300555.
PMID: 39292730
Background: Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral...
3.
Morpeth S, Venkatesh B, Totterdell J, McPhee G, Mahar R, Jones M, et al.
NEJM Evid
. 2024 Feb;
2(11):EVIDoa2300132.
PMID: 38320527
BACKGROUND: Nafamostat mesylate is a potent in vitro antiviral agent that inhibits the host transmembrane protease serine 2 enzyme used by severe acute respiratory syndrome coronavirus 2 for cell entry....
4.
Denholm J, Venkatesh B, Davis J, Bowen A, Hammond N, Jha V, et al.
Trials
. 2022 Dec;
23(1):1014.
PMID: 36514143
Background: SARS-CoV-2 infection is associated with a significant risk of hospitalisation, death, and prolonged impact on quality of life. Evaluation of new treatment options and optimising therapeutic management of people...
5.
Cheung N, Gilroy N, Hor A, Jose S, Kairaitis K, Nayyar V, et al.
Intern Med J
. 2022 Nov;
53(2):194-201.
PMID: 36369676
Background: Diabetes has been recognised as a major risk factor for COVID-19 mortality and hospital complications in earlier studies. Aims: To examine the characteristics of hospitalised COVID-19 patients with diabetes...
6.
Rockett R, Basile K, Maddocks S, Fong W, Agius J, Johnson-Mackinnon J, et al.
N Engl J Med
. 2022 Mar;
386(15):1477-1479.
PMID: 35263515
No abstract available.
7.
Vette K, Machalek D, Gidding H, Nicholson S, OSullivan M, Carlin J, et al.
Open Forum Infect Dis
. 2022 Feb;
9(3):ofac002.
PMID: 35169588
Background: As of mid-2021, Australia's only nationwide coronavirus disease 2019 (COVID-19) epidemic occurred in the first 6 months of the pandemic. Subsequently, there has been limited transmission in most states...
8.
Axfors C, Janiaud P, Schmitt A, Vant Hooft J, Smith E, Haber N, et al.
BMC Infect Dis
. 2021 Nov;
21(1):1170.
PMID: 34800996
Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of...
9.
Hasan T, Lim H, Case J, Hueston L, Bag S, Dwyer D, et al.
Aust N Z J Public Health
. 2021 Nov;
45(6):616-621.
PMID: 34761846
Introduction: In May 2020, The Communicable Diseases Network of Australia (CDNA) case definition introduced serological criteria to support the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present...
10.
Wehrhahn M, Brown S, Newcombe J, Chong S, Evans J, Figtree M, et al.
J Clin Virol
. 2021 Mar;
138:104797.
PMID: 33770657
A total of 1080 individual patient samples (158 positive serology samples from confirmed, predominantly mildly symptomatic COVID-19 patients and 922 serology negative including 496 collected pre-COVID) from four states in...